High-quality
real-world data

Generating high-validity real-world evidence requires high-quality RWD.

Accelerate clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives across all therapeutic areas using credible evidence developed from high-quality real-world data with measured accuracy, completeness, and traceability.

High-quality
real-world data

Generating high-validity real-world evidence requires high-quality RWD.

Accelerate clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives across all therapeutic areas using credible evidence developed from high-quality real-world data with measured accuracy, completeness, and traceability.

New times call for a powerful platform

For biopharma decision-makers, Verantos is making what seemed impossible, possible. Our high-validity RWE platform combines deep phenotyping — structured and unstructured data from electronic health records (EHR), artificial intelligence (AI), and accuracy determination — with linkage to exposure and outcomes data to answer today’s most challenging clinical questions.

Evidence you can trust

Proven reliability, 50% higher accuracy than the industry standard

Our Awards

Partner logo Verantos reached #224 on the 2022 Inc 5000 list
image alt testing

Meet increasing RWE demands

High-validity RWE – utilizing the entire patient record, deep phenotyping, AI-generated insights, and linked exposures and outcomes – makes it possible to understand how patient characteristics and behaviors affect health outcomes to predict the progression of a disease and a patient’s responses to therapy while also increasing the efficiency of R&D investments and accelerating time to market.

Magnifying Glass Icon

Get out of the danger zone

Studies based on traditional RWE leave franchises vulnerable to regulatory and market access concerns and commercial delay. High-validity studies run on our high-validity RWE platform provide accurate and believable evidence, enabling regulatory and reimbursement approvals. It is worth investing now in the RWE capabilities of the future.

Our Solutions

Pragmatic Registry

  • Scalable disease registries from high-reliability real-world data
  • Longitudinal disease severity, treatment, symptom control, resource utilization, and clinical outcome parameters
  • Safety and effectiveness profile of specific interventions

Our Partners

Partner logo Partner logo Partner logo Partner logo Partner logo Partner logo Partner logo

Credible evidence is a competitive advantage.

Credible evidence is a competitive advantage.